Cantor Fitzgerald reiterated an Overweight rating for aTyr Pharma on August 20, 2025.
2 reports, 2 independent
Updated Sep 22
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cantor Fitzgerald reiterated an Overweight rating for aTyr Pharma on August 20, 2025.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Cantor Fitzgerald reaffirmed overweight rating for Aligos Therapeutics.1 source
Cantor Fitzgerald reiterated an Overweight rating for aTyr Pharma.1 source
Keep exploring
The entities involved
-
Cantor Fitzgerald
American financial services company
- Multiple financial firms, including Raymond James, Wells Fargo, UBS, Cantor Fitzgerald, and KeyCorp, issued rating updates and target price changes on November 2, 2026.
- Barclays dropped its target price and set an underweight rating, while Cantor Fitzgerald also issued an underweight rating for Polestar.
-
aTyr Pharma
company in San Diego, United States
Nothing else this week.
-
Aligos Therapeutics, Inc.
Nothing else this week.
Related events
- Cantor Fitzgerald restated an overweight rating for Anteris Technologies Global Corp. on October 8, 2026.
- Cantor Fitzgerald restated an overweight rating and Royal Bank of Canada reduced its price objective for United Therapeutics.
- Cantor Fitzgerald reiterated an overweight rating for Sterling Infrastructure on November 1, 2026.
- Cantor Fitzgerald reiterated its 'overweight' rating on Oracle stock on June 11, 2026.
- Cantor Fitzgerald began coverage and issued rating, and Morgan Stanley upgraded price objective and rating for Silence Therapeutics.
Coverage
Newest first; wire copies grouped- dailypolitical.com
- Insider MonkeyATyr Pharma Rated as Overweight at Cantor Fitzgerald on Efzofitimod Expectations aTyr Pharma, Inc. (NASDAQ:ATYR) is one of the top multibagger penny stocks to buy, according to analysts. On August 4,